

Why communication is important for your project?

Simple....

If you want to be successful you need to

Communicate your results

Disseminate your outputs

We are here to help you as a multiplier...if you keep us in the loop!

Which material does the IMI office relies upon


- Periodic and final reports: importance of high quality publishable summary
- Project website: ideally it should be the “one stop shop”
- Publications (open access)
- Slide decks
- Interim reviews
- Close out meetings

Communication of science and technology results

All starts from the data....the importance of quality in research

Can We Trust Our Data?

Most Scientists Experienced Failure to Reproduce



90%

**scientist
think there
is a crisis**



Communication of project results to feed IMI progress analysis and reporting

– IMI PROGRESS ANALYSES

Socio-economic impacts of IMI projects


- [IMI Socio-economic Impact Assessment Expert Group - Final Report](#) (May 2016)
Read the associated [press release](#)
- [IMI's added value - project outputs linked to early socio-economic impacts](#) (Autumn 2015)

Bibliometric analyses of ongoing projects

- [Bibliometric analysis of ongoing projects: Innovative Medicines Initiative Joint Undertaking \(Eighth Report: August 2017\)](#)
[News article](#)
- [Bibliometric analysis of ongoing projects: Innovative Medicines Initiative Joint Undertaking \(Seventh Report: May 2016\)](#)
[News article](#)
- [Bibliometric analysis of ongoing projects: Innovative Medicines Initiative Joint Undertaking \(Sixth Report: June 2015\)](#)
[Executive Summary](#)
- [Bibliometric analysis of ongoing projects: Innovative Medicines Initiative Joint Undertaking \(Fifth Report: December 2014\)](#)
- [Bibliometric analysis of ongoing projects: Innovative Medicines Initiative Joint Undertaking \(Fourth Report: April 2014\)](#)
- [Bibliometric analysis of ongoing projects: Innovative Medicines Initiative Joint Undertaking \(Third Report: October 2013\)](#)
- [Bibliometric analysis of ongoing projects: Innovative Medicines Initiative Joint Undertaking \(Second Report: March 2013\)](#)
- [Bibliometric analysis of ongoing projects: Innovative Medicines Initiative Joint Undertaking \(First Report: October 2012\)](#)

Other reports and documents

- [Draft Code of Practice on Secondary Use of Medical Data in Scientific Research Projects](#)
This document, written by representatives of the IMI office and IMI projects, aims to provide a set of harmonised rules applicable to secondary use of medical data. It is intended to be useful to research projects involving multiple legal entities established in one or more EU Member States.
- [Report](#) - Patient involvement in IMI projects from Calls 1 to 6
- [Report](#) - Patients' awareness of IMI and views of patient involvement in research



IMI projects are successful in publishing impactful results!

How do we use your communication outputs and why they are very valuable for us



Annual Activity Report 2017

Copyright © 2018 Innovative Medicines Initiative

In accordance with Article 17 of the Statutes of IMI2 JU annexed to Council Regulation (EU) No 557/2014 of 6 May 2014 and with Article 20 of the Financial Rules of IMI2 JU.

The Annual Activity Report will be made publicly available following approval by the IMI Governing Board.

Annex 1 to the Decision of the IMI2 Governing Board no. IMI2 GB-DEC-2018-17 approved by the Governing Board of the Innovative Medicines Initiative 2 Joint Undertaking at the meeting of 26.06.2018

Document reference: IMI2/OUT/2017-03352


- Feed IMI KPI
- Material for IMI Success stories
- Feed the Table of projects outputs
- Presentations to IMI Advisory Bodies
- Presentations to the IMI Governing Board
- Presentations to Policy makers
- IMI communication material
- IMI website



IMI – Ecosystem for innovative collaborations


IMI is a **neutral platform** where **all involved** in drug development can engage in **open collaboration** on **shared challenges**.

All partners needed to find transformative solutions to **reduce late stage attrition, speed patient access** and **improve health outcomes** and find solutions for a sustainable healthcare system



KPI nr 7: Co-authorships and cross-sector publications between European researchers on IMI2 projects (sectors include academia, small and mid-sized companies, pharma, regulators, patient organisations, etc.).

Measures of success



News, Achievements, Success Stories



10 years of Europe's partnership
for health

[Home](#)

[About IMI](#)

[Get
involved](#)

[Apply
for funding](#)

[Projects
& results](#)

[News
& events](#)

[Resources
for projects](#)



[Home](#) | [Projects & results](#)

Projects & results



PROJECT FACTSHEETS

Learn more about our projects, including their goals, funding, participants, and latest news and results.



SUCCESS STORIES FROM PROJECTS

In-depth stories about some of our project successes, including interviews with project coordinators.



MAPS AND STATISTICS

Our projects have partners across Europe and beyond. Find them with the help of this interactive tool.




CATALOGUE OF PROJECT TOOLS

Accelerate your own research. Have a look at the list of accessible tools generated by our projects.



Contribute to the catalogue of project tools

EBISC	EBISC catalogue	Catalogue of human iPSC cells being made available to academic and commercial researchers for use in disease modelling and other forms of preclinical research	link	Free
-------	---------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------	------



Global supplier of iPSC lines

Cell Line Catalogue For customers For depositors About EBISC


Log in

iPSC line catalogue

801 cell line

Disease Donor sex Donor age Derivation

Name	Donor disease status	Genetic modification	Donor sex	Donor age	Derivation
EDi018-C	bipolar disorder	/	female		Sendai virus
ESi003-A	X-linked creatine transporter deficiency	/	male		Retrovirus
ESi004-A	Gaucher disease	/	female		Lentivirus expressing CRE recombinase



We want your success stories!

Support for patients with respiratory diseases

13/03/2019



IMI's PRO-active project has developed new patient-centred tools and approaches to help people with chronic obstructive respiratory disease (COPD) get more personalised treatments - a means to boost their activity levels, health and well-being.

COPD affects 1 in 10 of all people aged 50 and over and is a leading cause of death. The disease is characterised by breathlessness, coughing and often excessive mucus production, all of which make any physical activity uncomfortable and difficult for sufferers. In Europe alone, some 300 000 Europeans die each year from COPD.

Physical inactivity is a key predictor of death in patients with COPD. The IMI project PRO-active has developed new tools to help researchers and clinicians measure the impact of the disease on patients experience with physical activity and the physical difficulties patients encounter. This information can now be used to assess the impact of effective treatments on an outcome that is directly relevant to patients.

'Lack of physical activity is an indicator of mortality,' says project coordinator Thierry Troosters of the Katholieke Universiteit Leuven in Belgium. 'Patients with COPD who drop their physical activity levels are more likely to die than people who maintain those levels. We could already measure physical activity, but now we have a tool that captures how patients experience it.'

The new tools are providing doctors, nurses and other healthcare workers and researchers with unique information on the effect of treatment on their patients, he adds. They will also feed into the way new medicines and other interventions are assessed and benchmarked, based on patients' experiences.

A focus on patient experience

By combining wearable physical activity monitors with short daily surveys, researchers found an effective way to gauge symptom-related stress experienced when patients were active. Three different kinds of activity monitors were trialled to find the most sensitive ones, which are best suited for people with chronic diseases.

Input from patients was key to the development of the PRO-active tool. COPD sufferers themselves designed the user-friendly questions for the surveys and patient organisations were also given important managerial roles on the ethics committee board of the project.

'We want to get insights from the patients' perspective on how an intervention benefits them directly,' says Troosters, explaining how normally treatment testing focuses on physiological results, but not patient experiences.



As part of the results of the project, we present a link between the degree of severity of the disease and the level of physical activity. The link between the degree of severity of the disease and the level of physical activity is a key predictor of death in patients with COPD.

We need you to be a success! Let us know **timely** your good news!!

Success stories from projects

2018



Catalogue of project tools

In order to help scientists outside of our projects in their research efforts, we have started building a catalogue of accessible tools generated by our projects. Please keep in mind that this list is not comprehensive.

If you know of a tool which should be included in this catalogue please [contact us](#).

Show entries Search:

Project acronym	Resource	Short description	Link or contact	Access conditions
IPIE	EcoDrug	The ECOdrug database contains information on the evolutionary conservation of human drug targets in over 600 eukaryotic species. The interface allows users to identify human drug targets to 1000+... Show more	Link	Free
ADAPT-SMART	Glossary of definitions of common terms	ADAPT SMART aims to create a platform where the conditions and feasibility of medicines adaptive pathways to patients (MAPPs) implementation within the EU regulatory/legal context can be discussed... Show more	link	Free
AETIONOMY	AETIONOMY knowledge base	The most comprehensive knowledge base on Alzheimer's and Parkinson's disease worldwide	link	Free
BioVacSafe	tmod: Module enrichment tool	A new approach to gene module enrichment, which allows highly specific analysis of transcriptional modules in immune related analyses. This is coupled with novel approaches in visualization of gene... Show more	link	The tool is distributed with the GPL (GNU public license)
BTCure	Credible Refinement and Annotation of Functional Target	Credible Refinement and Annotation of Functional Targets (CRAFT) is a pipeline for the calculation, annotation and visualisation of credible SNP sets. The aim is to prioritise genetic variants for... Show more	link	Free
CHEM21	CHEM21 online learning platform	This platform comprises a range of free, shareable, and interactive educational and training materials created to promote the uptake of green and sustainable methodologies, with a particular focus on... Show more	link	Free
CHEM21	Massive Open Online Course in industrial biotechnology	Covers the key enabling technologies that underpin biotechnology research including enzyme discovery and engineering, systems and synthetic biology and biochemical and process engineering.	link	Free

A faster way to spot the tell-tale signs of cancer-causing drugs

08/06/2018

IMI's MARCAR project has identified potential biomarkers that could indicate how likely a drug is to cause cancer at an earlier stage of testing than is currently possible, which could save drug companies time and money – and lead to safer drugs reaching patients faster.



'The benefits of collaboration come through loud and clear' – an interview with the GETREAL project coordinator

22/05/2018

GETREAL developed new tools and resources for incorporating real-life data into drug development, which could increase confidence in new medicines and help to get them to patients more quickly. In an interview with the IMI Programme Office, project coordinator, Elaine Irving of GlaxoSmithKline explains the main project achievements, and why they wouldn't have been possible without IMI.



Tapping the full potential of Europe's health data

17/04/2018


IMI's EMIF project is helping researchers tap into Europe's treasure trove of electronic health data, saving them time and money in their quest to cure and develop better drugs for debilitating diseases. The effort has already led to promising findings linked to Alzheimer's and obesity.



'We made significant breakthroughs' – an interview with the PREDECT project coordinators

16/04/2018

IMI's PREDECT project developed new, much-improved laboratory models of cancer, which could improve the accuracy with which pharmaceutical companies predict the effectiveness of new drugs. In an interview the IMI Programme Office, project coordinator John Hickman of Servier, and academic coordinator Emmy Verschuren of the Institute for Molecular Medicine Finland at the University of Helsinki, explain the project's most significant breakthroughs, and how these achievements will help in the future search for new drugs.



'We made significant accomplishments in a very challenging field' – an interview with MIP-DILI project coordinators

09/04/2018

IMI's MIP-DILI project deepened the knowledge of the science behind drug-induced liver injury (DILI) and improved laboratory tests in use to predict DILI in the early stages of drug development. In an interview with the IMI Programme Office, Richard Weaver of Servier and academic coordinator, Kevin Park of the University of Liverpool, describe the project's most important achievements, and explain how they are already benefitting industry, academia, and patients, while at the same time reducing the use of animals in research.

